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Platinum-based regimens have not been proved to increase survival from advanced
prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers
have homologous recombination DNA (HRD) repair defects, and that such genomic
aberrations are synthetically lethal with both poly(ADP)-ribose polymerase inhibition
and platinum, has increased interest in the utilisation of these drugs against a subset of
these diseases. Here in we report three patients with advanced castration-resistant PCa
with HRD defects having exceptional responses to carboplatin.
© 2018 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).* Corresponding author. The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG,
United Kingdom. Tel. +44 2087224029; Fax: +44 208 642 7979.
.de-bono@icr.ac.uk (J.S. de Bono).E-mail address: Johann1. Introduction
A distinct subgroup of patients with metastatic castration-
resistant prostate cancer (mCRPC) [1] carry germline or
somatic defects in DNA repair genes. Some of these
alterations associate with significant and long-lastinghttps://doi.org/10.1016/j.eururo.2018.09.048
0302-2838/© 2018 The Author(s). Published by Elsevier B.V. on behalf of Eur
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncresponses to poly (ADP-ribose) polymerase (PARP) inhibi-
tors [2]. In particular, homologous recombination defects
(HRD) are also known to confer sensitivity to platinum
derivatives in diverse cancers [3,4]. Nevertheless, platinum
has not been routinely used for the care of advanced
prostate cancer (PCa) as the only randomised phase III trialopean Association of Urology. This is an open access article
-nd/4.0/).
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mCRPC patients failed to show overall survival benefit
[5]. Here we report on three patients with metastatic PCa
with strong family histories and different DNA repair
defects who have had remarkable and highly durable
responses to platinum-based treatment and unequivocal
clinical benefit. Interestingly, no specific DNA repair defects
were detected in the first patient but whole exome
sequencing revealed a mutational signature with a high
homologous recombination repair deficiency score. In the
second and third patient, deleterious germline BRCA2 and
ATM mutations, respectively, were identified.
Patient 1 was aged 52 yr when he presented in January
2014 with adenocarcinoma of the prostate with extensive
nodal, lung, and bone metastatic disease and a relatively
low prostate-specific antigen (PSA: 8.8 ng/ml). His family
history was highly suspicious for a cancer syndrome (Fig. 1).
He was treated initially with androgen deprivation therapy
(ADT) and radiotherapy (RT) to the thoracic spine but
progressed after 4 mo with multiple liver metastases and
worsening of the lung lesions. Docetaxel, cabazitaxel (four
cycles each), and enzalutamide (two cycles) administered in
sequence failed to provide a response. A liver biopsy at this
time confirmed the presence of prostate adenocarcinoma
(Fig. 2). Having exhausted all the standard treatment
options, single-agent carboplatin was initiated at the target
dose of area under the curve (AUC) 6 (total dose of 1100 mg)
based on ethylenediamine tetra acetic acid. The first
restaging after the second cycle showed a dramatic
[(Fig._1)TD$FIG]
Fig. 1 – Family tree of patient 1.
H&N cancer = head and neck cancer.radiological response (70% reduction of the measurable
disease) with further regression until cycle 11 when
treatment was discontinued due to prolonged neutropenia.
After 10 mo, he presented with symptomatic liver disease
and a solitary cerebellar lesion. Re-challenge with carbo-
platin was once again successful, with regression of the
cerebellar lesion indicating carboplatin delivery to the brain
(Fig. 3). CyberKnife of his solitary brain lesion was
administered after two cycles of carboplatin, which was
resumed 2 mo after this RT, for four additional cycles but
then again stopped due to persistent neutropenia. Restaging
in October 2017, 2 mo after carboplatin interruption,
indicated progression of the liver metastases and stable
disease elsewhere. In February 2018, after participation in a
phase I clinical trial, he was re-challenged for the third time
with carboplatin. Three years after commencing single-
agent carboplatin, he is still very well and responding to the
same agent and continuous ADT (Fig. 4).
We analysed germline and somatic cancer DNA with
next-generation sequencing (NGS) using a targeted panel of
DNA repair genes at more than 5000-fold depth, as well as
with the BROCA panel (which also covers intronic and
flanking regions of genes documented to predispose to
cancer) at the University of Washington (Dr. Colin
Pritchard), and finally whole exome sequencing (WES) of
his liver biopsy at two separate laboratories (Ann Arbor,
Michigan and The ICR, London). None of these assays were
able to identify pathogenic defects in canonical DNA repair
genes (Fig. 5). Immunohistochemistry showed nomismatch
[(Fig._2)TD$FIG]
Fig. 2 – Liver biopsy of patient 1 showing poorly differentiated adenocarcinoma with minor degree of neuroendocrine differentiation. There is strong
ERG and androgen receptor expression, focal positivity for prostate-specific antigen, and some neuroendocrine features: focal expression of CD56,
synaptophysin, chromogranin, and neuron-specific enolase (not shown).
AR = androgen receptor; PSA = prostate-specific antigen.
[(Fig._3)TD$FIG]
Fig. 3 – A male patient aged 54 yr with metastatic castration- resistant prostate cancer showing incremental radiological response after two cycles
(middle column) and six cycles (right column) of carboplatin. (A) Coronal computed tomography (CT)-enhanced images showing incremental
radiological response with almost complete resolution of the soft tissue disease associated with lytic right iliac bone metastasis (black circle). (B)
Coronal CT-enhanced images showing dramatic reduction in the total liver metastatic burden and resolution of the hepatomegaly. Note the
intralesional calcification associated with response. (C) Axial-enhanced CT brain images showing good radiological response to carboplatin challenge of
the solitary left cerebellar metastasis after two cycles of treatment (middle column) with further improvement after CyberKnife and further
carboplatin; note intralesional calcification.
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[(Fig._4)TD$FIG]
Fig. 4 – Prostate-specific antigen responses on treatments in patient 1.
[(Fig._5)TD$FIG]
Fig. 5 – Circos plot of the genetic alterations in patient 1 based on the data generated from tumour-normal paired exome sequencing. Inner track
indicates the type of the mutations and the genes that have the mutation. The middle and outer track indicate the B-allele frequency and logR ratio,
respectively, which is derived from copy number alteration analysis.
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(ATM) expression. WES data analysis, however, using
multiple bioinformatic approaches, confirmed a mutational
signature and genome scars associated with HRDs (Fig. 6)
[6]. Since ATM loss does not cause an HRD signature, these
data indicate a different genomic alteration [7].
Patient 2 was diagnosed in 2002 at the age of 37 yr with
adenocarcinoma of the prostate, with a PSA at presentation
of 293 ng/ml, a Gleason score of 8 in prostate biopsies, and
metastatic bone disease. He was commenced on ADT and
treated on a clinical trial regimen at Memorial Sloan
Kettering Cancer Center with six cycles of carboplatin,
paclitaxel, and estramustine, achieving a PSA nadir of 0.5 ng/
ml. Following a rise in his PSA to 0.7 ng/ml 6 mo later, he
received radical RT to the prostate and continued ADT until
7 yr later, when he developed castration-resistant disease.
Subsequently, abiraterone was initiated for 2.5 yr with a
good biochemical response and radiological stability. At this
time point, hewas referred to the RoyalMarsden; as he had a
strong family history of malignancy (Fig. 7), we performed
NGS of his tumour tissue from a fresh bone biopsy. This
demonstrated a BRCA2 frameshift truncating mutation
(c.4876_4877delAA, p.Asn1626Serfs*12), confirmed to be
of germline origin, with loss of the wild type allele. He
entered a phase I trial of olaparib at 200 mg bid in
combinationwith an ataxia telangiectasia and RAD3-related
protein inhibitor but had no PSA decline; however, he did
have radiological stability lasting for 4 mo. In light of the
[(Fig._6)TD$FIG]
Fig. 6 – Distribution of three types of homologous recombination defect (HRD
(n = 228). Red colour bar labels patient 1 HRD score.
CRPC = castration-resistant prostate cancer; HRD = homologous recombinationextraordinary previous response to carboplatin and pacli-
taxel, the patient was treated again with six cycles of
carboplatin (AUC 5) and docetaxel (75 mg/m2[2_TD$DIFF]), achieving a
44% PSA decline. On diffusion-weightedmagnetic resonance
imaging, the majority of his metastatic bone disease showed
features consistent with disease regression (including
disease at T6, T7, and T12); however, a large bonemetastasis
replacing his entire seventh right rib presented residual
hypercellular disease activity. This seventh right rib became
symptomatic with pain despite having been previously
irradiated with a single fraction of 8 Gy (Fig. 8). He was,
therefore, advised to pursue palliative metastatic seventh
right rib resection by thoracotomy. In 2018, 15 yr after his
original diagnosis, the patient remains well with on-going
continuous ADT and oligorecurrent disease at T6 which has
recently been treated with CyberKnife irradiation.
Patient 3 was aged 66 yr in June 2015 when hewas found
to have a slightly elevated PSA (5.38 ng/ml) and an enlarged
prostate, with biopsies confirming the diagnosis of prostate
adenocarcinoma with neuroendocrine differentiation and a
Gleason score of 4 + 5 (Fig. 9). A choline positron emission
tomography-computed tomography scan showed positive
pelvic lymph nodes and multiple bone metastases. He was
treated with ADT and six cycles of docetaxel but progressed
on this after 6 mo despite achieving castrate levels of
testosterone. At this stage, in consideration of his strong
family history (Fig. 10), he underwent genetic testing
which identified a pathogenic germline mutation in ATM) score in a cohort of metastatic castration-resistant prostate cancer
defect.
[(Fig._7)TD$FIG]
Fig. 7 – Family tree of patient 2.
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his tumour was confirmed by immunohistochemistry.
Furthermore, NGS analysis detected a TSC2 mutation (splice
site donor Ex39), with loss of the other copy of TSC2,which is
highly likely to be pathogenic. He was ineligible for a PARP-
inhibitor trial since he developed disseminated intravascular
coagulation with G3 thrombocytopenia as well as cauda
equina syndrome requiring external beam radiotherapy to
T12 to L3. He was subsequently commenced on single-agent
carboplatin at the initial target doseofAUC4,whichwas then
escalated to AUC 5 after two cycles as his platelets count
normalised. His PSA significantly declined from 159 ng/ml to
a nadir of 36 ng/ml but then increased despite two further
cycles of treatment; radiologically, there was no evidence of
progression (Fig. 11). We continued treatment with carbo-
platin but added cabazitaxel at a dose of 20 mg/m2 with a
further PSA decline from82 ng/ml to 7.6 ng/ml. He continues
on the same treatment combined with continuous ADTwith
responding disease as of May 2018.
2. Discussion
Platinum-based chemotherapy has demonstrated impres-
sive anti-tumour activity in somemCRPC patients; however,little published data are available on the different tumour
DNA repair defects associated with platinum sensitivity.
These three patients shared some atypical clinical features:
a strong family history for cancer, presentation with
metastatic disease, young age at diagnosis, and low PSA
levels relatively to the extent of their metastatic disease.
Interestingly, the first two patients were given carboplatin
based solely on these clinical characteristics. The availabili-
ty of NGS subsequently allowed us to elucidate the
underlying genomic characteristics of these tumours.
The first patient had exhausted all of the standard
treatment options and had rapidly progressive symptomatic
disease before initiation of carboplatinwhich has given him
further more than 3 yr of disease control and excellent
quality of life. We were unable to identify a specific genetic
defect responsible for his remarkable platinum sensitivity
althoughWES demonstrated amutational signature of HRD.
The second patient has a germline BRCA2 mutation
previously reported to confer a poorer prognosis [8];
however, impressively, he is still alive 15 yr later which
compares favourably to the median survival of 6 yr on the
CHAARTED trial [9] and 6.4 yr on the STAMPEDE trial
[10]. These data suggest that as with ovarian cancer,
platinum treatment may convert this aggressive disease
[(Fig._9)TD$FIG]
Fig. 9 – Histology of patient 3 showing prostate adenocarcinoma with significant neuroendocrine differentiation. Immunohistochemistry shows that
the tumour cells are very focally positive for prostate-specific antigen and negative for PSPA. Of note, tumour cells were negative for CD56 and
chromogranin and positive (90%) for synaptophysin. The tumour cells lack nucleoli, have fine granular “salt-and-pepper” chromatin, and form
occasional loose rosettes.
[(Fig._8)TD$FIG]
Fig. 8 – Coronal diffusion-weighted imaging (DWI; b900 s/mm2), coronal fused T2W-DWI and axial apparent diffusion coefficient images (ADC) through
the seventh rib showing a good response after six cycles of carboplatin (AUC5) and docetaxel with reduction in tumour diffusion value and increase in
mean tumour ADC (>35%) of most of the metastatic bone disease but heterogeneous ADC values in the seventh rib in keeping with residual focal areas
of low ADC (white arrows), suggestive of residual high tumour cellularity/active disease.
ADC = apparent diffusion coefficient; DWI = diffusion-weighted imaging.
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Fig. 10 – Family tree of patient 3.
[(Fig._11)TD$FIG]
Fig. 11 – Colour-coded coronal maximum intensity projection diffusion-weighted imaging showing (b900 s/mm2) incremental improvement with
reduction in the tumour diffusion volume accompanied by increase in apparent diffusion coefficient values. Of note are focal areas such as in the left-
sided ribs or in the bony pelvis (white arrows) showing lack of improvement throughout the studies in keeping with tumour response heterogeneity.
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presented with a deleterious germline ATM mutation, and
his response to carboplatin arguably supports the functional
impact of this genomic aberration.In conclusion, these case series suggest the efficacy of
carboplatin in metastatic prostate cancer with DNA repair
defects. Further clinical trials are warranted to support its
use in this subset of patients. Our report indicates that
E U RO P E AN URO LOGY 7 5 ( 2 019 ) 18 4 – 19 2192treatment selection can be facilitated by family history
records as well as NGS of germline and somatic cancer DNA.Conflicts of interest: The authors have nothing to disclose.
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EU-ACME questionPlease visit www.eu-acme.org/europeanurology to an-
swer the following EU-ACME question online (the
EUACME credits will be attributed automatically).Question:DNA repair defects are relatively common in advanced
prostate cancer and can be heritable. Which of the
following is incorrect:
A. Approximately 10–12% of all patients with metastatic
prostate cancer have deleterious and heritable germ-
line mutations in DNA repair genes.
B. Approximately 20–30% of advance prostate cancers
have somatic, deleterious, genomic aberrations in DNA
repair genes.
C. BRCA1 is the commonest DNA repair gene mutation
found in prostate cancer.
D. Consideration must be given to germline DNA testing
of all patients with metastatic prostate cancer.
E. Patents with ATM loss prostate cancers can respond to
platinum and PARP inhibitors.References
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